

The following claims are presented for examination:

1. (currently amended) A drug delivery device comprising: a drug; and a vascular implant a wire mesh intravascular stent having a blood-contacting surface; and a stent insert comprising a helical formation, made from a polymer, on the blood contacting surface, the helical formation comprising at least one fin and having a helix angle of between 8° and 20° and being capable of inducing helical flow of blood flowing past the helical formation, and the drug being releasably associated with the helical formation of the vascular implant stent insert.

2. (currently amended) A drug delivery device according to claim 1 wherein the drug is mixed into the material polymer from which the helical formation is made.

3. (previously presented) A drug delivery device according to claim 1 wherein the drug is coated onto the surface of the helical formation.

Claims 4-16 (cancelled)

17. (currently amended) A drug delivery device according to **claim-4 claim 1** wherein the polymer is a polymer foam.

18. (currently amended) A drug delivery device according to **claim-4 claim 1** wherein the polymer is selected from the group consisting of: polyamide, polyester, and polyurethane.

19. (currently amended) A drug delivery device according to **claim-4 claim 1** wherein the drug is bound onto the cellular structure of the polymer.

20. (previously presented) A drug delivery device according to claim 1 wherein the drug is selected from the group consisting of: an anticoagulant, an antiplatelet agent, an angiogenesis inhibitor, a cyclooxygenase inhibitor, a gene therapy agent, and a mixture of two or more of said drugs.

21. (currently amended) A drug delivery device according to claim 1 wherein the vascular implant is selected from the group consisting of: an intravascular stent insert, a vascular graft, and insert is a stent graft.

22. (currently amended) A drug delivery device according to **claim-21 claim 1** wherein the vascular implant is a stent and the drug delivery device further comprises a sleeve positioned surrounding and/or within the intravascular stent.

23. (previously presented) A drug delivery device according to claim 22 wherein the sleeve is made from expanded PTFE.

24. (cancelled)

25. (previously presented) A drug delivery device according to claim 1 wherein at least one further drug is provided releasably associated with the helical formation.

Claims 26 and 27. (cancelled)

28. (currently amended) A drug delivery device according to ~~claim 27~~ **claim 1** wherein the at least one fin has the shape of a right-angle triangle in cross-section.

29. (currently amended) A drug delivery device according to ~~claim 27~~ **claim 1** wherein the at least one fin has the shape of an isosceles triangle in cross-section.

30. (currently amended) A drug delivery device according to ~~claim 27~~ **claim 1** wherein the at least one fin has the shape of a bell in cross-section.

Claims 31 and 32. (cancelled)